Does Insurance Cover CAR T-Cell Therapy? Costs, Denials, and Appeals

Yes, insurance generally does cover CAR T-cell therapy. Medicare, most private plans, and most state Medicaid programs will pay for it when the therapy is used for an FDA-approved cancer indication, the patient has already tried standard treatments, and care is delivered at a qualified center. Coverage is not automatic. Expect prior authorization, detailed clinical documentation, and sometimes a fight over network status or medical necessity before the first infusion is approved.

The stakes make all of that worth understanding. The drug alone runs between roughly $460,000 and $595,000 depending on the product, and total per-patient costs including hospitalization and management of side effects routinely exceed $1 million.1ASH Clinical News. CAR T-Cell Therapies Predicted to Cost More Than $1 Million Per Patient A denial you don’t challenge becomes a bill you can’t pay.

What Has To Be True For Coverage

Three conditions do most of the work in any coverage decision.

First, the patient’s diagnosis has to match an FDA-approved indication for the specific product being prescribed. The FDA has approved several CAR T-cell products, each tied to particular blood cancers like certain lymphomas, acute lymphoblastic leukemia, and multiple myeloma.2U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products A product approved for one cancer type is not automatically covered for another.

Second, prior therapies generally have to have failed. Insurers want documented evidence that standard treatments such as chemotherapy or stem cell transplants were tried and either didn’t work or stopped working.

Third, treatment has to happen at a facility equipped to deliver it. CAR T-cell therapy is available only at specialized cancer centers that can manage cytokine release syndrome and neurotoxicity, the two most serious side effects.

Medicare Coverage

Medicare covers CAR T-cell therapy under National Coverage Determination 110.24. The treatment must be used for an FDA-approved indication or for another use supported by a CMS-approved drug reference compendium, and the therapy must be autologous, meaning it uses the patient’s own cells.3Centers for Medicare & Medicaid Services. National Coverage Determination – Chimeric Antigen Receptor (CAR) T-cell Therapy

A recent rule change widened the facility options. CMS used to require that CAR T-cell therapy be given at a facility enrolled in the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. As of June 26, 2025, the FDA eliminated REMS for all CAR T-cell products, and CMS dropped the facility requirement along with the associated billing modifier.4Centers for Medicare & Medicaid Services. Chimeric Antigen Receptor T-Cell Therapy Claims: End of Risk Evaluation Mitigation Strategy and KX Modifier Requirement Medicare patients are no longer limited to REMS-enrolled centers, though the facility still has to be able to handle the side effects.

Billing can go through Part A when the therapy is delivered during an inpatient stay, or through Part B when delivered in a hospital outpatient department. Most patients are admitted as inpatients because the monitoring period typically requires a multi-week hospital stay.

Medicare also covers routine costs when CAR T-cell therapy is given as an investigational agent in a qualifying clinical trial, as long as the trial meets the requirements of NCD 310.1.5Centers for Medicare & Medicaid Services. NCD – Routine Costs in Clinical Trials (310.1)

Private Insurance Coverage

Most private insurers cover CAR T-cell therapy when the patient’s diagnosis falls within an FDA-approved indication and prior treatments have failed. Policies generally follow FDA labeling and National Comprehensive Cancer Network guidelines to decide whether the therapy is appropriate.

Network restrictions matter more here than with routine care. CAR T-cell therapy is available only at specialized centers, and many may be out of your insurer’s network. A plan that limits reimbursement to in-network providers can respond to an out-of-network treatment center with a much higher cost share or a flat denial. Some policies exclude out-of-country treatment entirely.

Single Case Agreements

When the right treatment center is outside your network, a single case agreement can bridge the gap. It is a one-time contract between your insurer and an out-of-network provider that lets you receive treatment at your in-network cost-sharing rate. To request one, confirm the out-of-network provider is willing to negotiate, then call the number on your insurance card and explain why you need that specific facility. You generally need to show that no in-network provider can deliver the same specialized care, or that geographic barriers make in-network options impractical. If approved, the agreement covers only the specific treatment and only for its duration.

Employer-Sponsored Plans

Large employers who self-insure set their own coverage terms within federal guidelines. Some have negotiated outcomes-based contracts with manufacturers, meaning the plan only pays if the patient responds within a set period. Others use specialty pharmacy carve-outs or centers-of-excellence programs that direct patients to specific sites in exchange for negotiated pricing. If you’re covered through an employer, HR or your benefits administrator can tell you exactly what applies.

Medicaid Coverage

Medicaid coverage varies significantly by state. Federal law generally requires state programs to cover FDA-approved drugs for their labeled indications, but states apply the rules differently. Some cover CAR T-cell therapy to the full extent of the FDA-approved label. Others impose restrictions beyond the label, such as narrower age limits, stricter disease-severity thresholds, or requirements to have failed more prior treatments than the label specifies. Some states have no published policy at all. Initial denials are common for Medicaid patients even when they meet the labeled indication, often with requests for clinical documentation beyond what the label requires.

Prior Authorization: What To Prepare

Virtually every insurer requires prior authorization. The process can take weeks, so start early and keep organized records of every submission.

Your oncologist builds the case. That means assembling your full treatment history, pathology reports, imaging results, and evidence that prior therapies failed or that the cancer relapsed. Insurers want to see alignment with the FDA-approved indication for the specific product and with NCCN clinical guidelines. Some also request recent lab work or genetic markers confirming the cancer type targeted by the therapy.

Facility qualifications matter too. Even though CMS no longer requires REMS enrollment, private insurers may still have their own certification standards.6Centers for Medicare & Medicaid Services. CMS Transmittal 13432 – Removal of Chimeric Antigen Receptor (CAR) T-cell Therapy and Risk Evaluation Mitigation Strategy (REMS) Many require that the center have experience managing cytokine release syndrome and neurotoxicity, and some require specific training or board certifications for the prescribing oncologist. Confirming your facility meets your insurer’s requirements before starting the authorization process prevents wasted time and rejected claims.

Common Exclusions

Even plans that cover CAR T-cell therapy draw lines around what they will pay for.

Off-Label Use

If your oncologist recommends CAR T-cell therapy for a cancer type not listed on the product’s FDA-approved label, most insurers will deny coverage. This is true even when early research shows promise. Medicare is somewhat more flexible, covering uses supported by CMS-approved drug compendia even when the specific use isn’t on the FDA label.3Centers for Medicare & Medicaid Services. National Coverage Determination – Chimeric Antigen Receptor (CAR) T-cell Therapy Private insurers generally don’t extend the same flexibility.

Experimental or Investigational Classification

Insurers may classify newer variations, modified protocols, or products still in clinical trials as experimental, which typically triggers an automatic denial. Patients in this situation may be able to enroll in a clinical trial, where the investigational therapy itself is provided at no charge and routine medical costs may still be covered by insurance.

Clinical Trial Costs

For patients whose cancer doesn’t match a currently approved indication, clinical trials are often the most practical path to receiving CAR T-cell therapy. Medicare covers routine costs associated with qualifying clinical trials, including hospitalization and standard tests, when the trial has therapeutic intent and meets federal requirements.5Centers for Medicare & Medicaid Services. NCD – Routine Costs in Clinical Trials (310.1) Most private plans subject to the ACA must similarly cover routine trial costs. The experimental therapy itself is typically paid for by the trial sponsor.

If Your Claim Is Denied

Denials happen frequently even when patients appear to meet every requirement. Common reasons include missing paperwork, coding errors, disputes over medical necessity, or the insurer classifying the approach as investigational. A denial is not the final word. Many are overturned on appeal.

Internal Appeal

The first step is an internal appeal with the insurer. The insurer must provide a written explanation of the denial, including the specific reasons and the steps to challenge it. You can submit additional medical records, corrected billing codes, or a more detailed letter of medical necessity from your oncologist. Under the ACA, the insurer must complete its internal review within 30 days for services you haven’t received yet, or within 60 days for services already provided.7HealthCare.gov. Appealing a Health Plan Decision If delays could seriously harm you, request an expedited appeal, which lets you pursue internal appeal and external review simultaneously.

External Review

If the internal appeal fails, you can request an independent external review. A third-party medical expert evaluates whether the denial was justified. Under the ACA, virtually all non-grandfathered health plans must offer this option, and you have at least four months from the date of the final internal denial to file.8Centers for Medicare & Medicaid Services. External Appeals Standard external reviews must be decided within 45 days. Expedited reviews for urgent medical situations must be resolved within 72 hours.9HealthCare.gov. External Review If the reviewer sides with you, the insurer must provide coverage.

Building A Strong Appeal

Appeals that succeed tend to have thorough documentation behind them. Gather all pathology reports, imaging, and treatment records showing your cancer relapsed or resisted prior therapies. A detailed letter of medical necessity from your oncologist explaining why CAR T-cell therapy is the most appropriate remaining option carries significant weight. Supporting evidence like peer-reviewed studies or references to NCCN guidelines helps, particularly when the insurer’s denial hinged on medical necessity. Keep a log of every phone call, submission date, and document sent. You will need that paper trail if the dispute escalates.

What You Still Pay Out Of Pocket

Even with full coverage, deductibles, copayments, and coinsurance all apply. For 2026, the ACA caps annual out-of-pocket spending at $10,600 for individual coverage and $21,200 for family coverage. Patients on high-deductible or high-coinsurance plans will hit those maximums quickly given the total cost of treatment. Because the limits reset each calendar year, patients whose treatment and follow-up care span a year boundary could face two rounds of maximum cost sharing.

Indirect costs pile up alongside the medical bills. CAR T-cell therapy is available only at major cancer centers, and many patients travel long distances and stay near the facility for weeks during treatment and initial monitoring. Lodging, transportation, meals, and lost wages during recovery are rarely covered by insurance. Some insurers offer limited travel reimbursement, but this benefit is uncommon in standard plans.

Financial Assistance Programs

Several sources can help close the gap between what insurance covers and what you actually owe. Drug manufacturers offer copay assistance programs that cover out-of-pocket costs for the therapy itself for commercially insured patients. These programs generally do not extend to patients on Medicare, Medicaid, or other government insurance. Eligibility and coverage limits vary by manufacturer and product.

Nonprofits also provide support. BMT InfoNet offers one-time grants for non-medical expenses like housing, transportation, and food during treatment. The Leukemia & Lymphoma Society provides financial assistance to blood cancer patients. Help Hope Live helps patients raise funds and manage payment of medical bills. Hospital social workers at the treatment center are usually the best starting point for identifying which programs you qualify for.

Long-Term Follow-Up Coverage

Costs don’t end with the infusion. In January 2024, the FDA added a boxed warning to all currently approved CAR T-cell products highlighting the risk of secondary T-cell cancers, which can appear as soon as weeks after infusion and may be fatal.10U.S. Food and Drug Administration. FDA Requires Boxed Warning for T Cell Malignancies Partly because of this risk, the FDA recommends 15 years of safety monitoring for patients who receive CAR T-cell products manufactured using integrating viral vectors, which includes most approved therapies.

That 15-year window means regular follow-up visits, blood tests, and imaging for years after treatment. Insurance generally covers these as ongoing cancer care, but expect recurring copays and deductibles over a long horizon. If you change plans during that period, the new plan cannot deny monitoring as a pre-existing condition under the ACA, but you may need to re-establish care at a new treatment center and go through fresh prior authorization for continued follow-up at specialized facilities.